Welcome to our dedicated page for Black Diamond Therapeutics SEC filings (Ticker: BDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Black Diamond Therapeutics often means diving into long 10-Ks packed with trial protocols, cash-burn tables and mutation-specific risks. If you have ever typed “Black Diamond Therapeutics quarterly earnings report 10-Q filing” or hunted for “Black Diamond Therapeutics insider trading Form 4 transactions,” you know the search can be tedious. Search engines may list dozens of links—few actually explain the science or the numbers.
Stock Titan solves that problem. Our AI parses every submission the second it appears on EDGAR, delivering Black Diamond Therapeutics SEC filings explained simply. Need the Black Diamond Therapeutics annual report 10-K simplified? Done. Want Black Diamond Therapeutics Form 4 insider transactions real-time or an 8-K material events explained? You’ll get concise summaries, key metrics and side-by-side trend views without reading hundreds of pages. It’s understanding Black Diamond Therapeutics SEC documents with AI—faster and clearer.
For a precision-oncology company, the details investors monitor are unique. This page connects each filing type to those decision points:
- Cash-runway projections extracted from every quarterly earnings report 10-Q.
- Pipeline milestones and trial updates flagged in 8-Ks—Black Diamond Therapeutics 8-K material events explained.
- Compensation and governance highlights from the proxy statement executive compensation sections.
- Patterns in Black Diamond Therapeutics executive stock transactions Form 4 before material announcements.
- Actionable earnings report filing analysis linking R&D spend to MasterKey therapy progress.
Follow filings in real time, receive alerts for Black Diamond Therapeutics SEC events, and turn raw disclosures into clear insight—no more document hunting.
Director Ali Behbahani of Black Diamond Therapeutics reported acquiring 6,170 shares of common stock at $2.33 per share on June 20, 2025. The shares were issued as compensation for annual services as a non-employee director, in lieu of cash compensation under the company's Fifth Amended and Restated Non-Employee Director Compensation Policy.
Following the transaction, Behbahani directly owns 77,150 shares and indirectly controls 4,448,757 shares through NEA 16 GP, LLC, where he serves as a manager. The indirect ownership is through a complex structure involving NEA Partners 16, L.P. and New Enterprise Associates 16, L.P., though Behbahani disclaims beneficial ownership of these shares under Section 16 rules.
This Form 4 filing demonstrates continued insider engagement through equity-based compensation, with the director choosing stock over cash compensation, potentially indicating confidence in the company's future prospects.
Black Diamond Therapeutics Director Prakash Raman acquired 5,526 shares of common stock at $2.33 per share on June 20, 2025, bringing their total direct ownership to 22,519 shares.
Key details of the transaction:
- The shares were issued under the company's Fifth Amended and Restated Non-Employee Director Compensation Policy
- The acquisition represents an election to receive stock in lieu of cash compensation for annual services as a non-employee director
- The reported price is based on the closing market price of the company's common stock on June 18, 2025
- The transaction was reported via Form 4 filing, executed by Attorney-in-Fact Brent Hatzis-Schoch
FAQ
What is the current stock price of Black Diamond Therapeutics (BDTX)?
What is the market cap of Black Diamond Therapeutics (BDTX)?
What is the core focus of Black Diamond Therapeutics?
How does Black Diamond Therapeutics differentiate itself in the competitive oncology market?
What types of cancer are the company’s therapies targeting?
What is the significance of a tumor-agnostic approach?
What are MasterKey therapies?
How does the Mutation-Allostery-Pharmacology platform work?
What are the primary challenges faced by clinical-stage oncology companies like Black Diamond Therapeutics?
How does Black Diamond Therapeutics address drug resistance in cancer?
